NCT05710809

Brief Summary

The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times/week can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
16mo left

Started Feb 2023

Longer than P75 for not_applicable colorectal-cancer

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Feb 2023Sep 2027

First Submitted

Initial submission to the registry

January 16, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 2, 2023

Completed
18 days until next milestone

Study Start

First participant enrolled

February 20, 2023

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

April 6, 2025

Status Verified

April 1, 2025

Enrollment Period

4.2 years

First QC Date

January 16, 2023

Last Update Submit

April 2, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Dynamic Gait Index (DGI)

    Between-group difference in change in walking balance assessed with Dynamic Gait Index (DGI) scored on a 0-24 point total scale. Higher score means better outcome

    Three months

  • 30 second Sit-to-Stand Test (30STS)

    Between-group difference in lower limb muscle strength and endurance

    Three months

Secondary Outcomes (11)

  • Falls

    Baseline, two, four, six, eight, ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, and twenty-four weeks

  • Hospital contacts due to falls

    Baseline, three and six months

  • Balance disabilities/dizziness

    Baseline, three and six months

  • Fear of falling

    Baseline, three and six months

  • Health related quality of life

    Baseline, three and six months

  • +6 more secondary outcomes

Other Outcomes (17)

  • Walking speed

    Baseline, three and six months

  • Postural control

    Baseline, three and six months

  • Vestibular function

    Baseline, three and six months

  • +14 more other outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Patients in the intervention groups will receive neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions

Other: Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement

Usual care group

NO INTERVENTION

Patients in the usual care groups will receive standard treatment with neoadjuvant, adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner

Interventions

Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions

Intervention group

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Meet the criteria of the oncological departments of receiving neoadjuvant, adjuvant or first line palliative chemotherapy for colorectal cancer
  • ≥65 years of age at the time of signing the informed consent form
  • Able to speak and read Danish, and to provide a signed informed consent form
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2

You may not qualify if:

  • Chemotherapy treatment within two years and sequelae of neuropathy, or symptoms of dizziness or vertigo, or balance disturbance
  • Severe physical disability that hinders physical exercise
  • Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial
  • Inability to sign informed content
  • Patients who have had a consultation in the geriatric outpatient clinic within the past six months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Copenhagen University Hospital - Rigshospitalet

Copenhagen, 2400, Denmark

NOT YET RECRUITING

Copenhagen University Hospital - Herlev and Gentofte Hospital

Herlev, 2730, Denmark

RECRUITING

Related Publications (1)

  • Piper KS, Suetta C, Schou JV, Ryg J, Andersen HE, Langevad LV, Evering D, Mikkelsen MK, Lund C, Christensen J. The SaVe project - Sarcopenia and Vertigo in aging patients with colorectal cancer: A study protocol for three randomized controlled trials. J Geriatr Oncol. 2024 May;15(4):101770. doi: 10.1016/j.jgo.2024.101770. Epub 2024 Apr 16.

MeSH Terms

Conditions

Colorectal NeoplasmsSarcopeniaVertigoNeoplasmsMotor Activity

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesMuscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsVestibular DiseasesLabyrinth DiseasesEar DiseasesOtorhinolaryngologic DiseasesBehavior

Central Study Contacts

Katrine S Piper, PhD-Student

CONTACT

Jan Christensen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Investigator = Statistician
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior researcher, Head of research

Study Record Dates

First Submitted

January 16, 2023

First Posted

February 2, 2023

Study Start

February 20, 2023

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

April 6, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

On reasonable request

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE

Locations